Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus

Ketty Peris, Lisa Licitra, Paolo A. Ascierto, Renzo Corvò, Marco Simonacci, Franco Picciotto, Giulio Gualdi, Giovanni Pellacani, Armando Santoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

30 Citazioni (Scopus)

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. BCC can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or unresectable tumors can be difficult to manage. Until recently, no approved systemic therapy was available for locally advanced or metastatic BCC inappropriate for surgery or radiotherapy. Vismodegib provides a systemic treatment option. However, a consensus definition of advanced BCC is lacking. A multidisciplinary panel with expertise in oncology, dermatology, dermatologic surgery and radiation oncology proposes a consensus definition based on published evidence and clinical experience.
Lingua originaleEnglish
pagine (da-a)703-712
Numero di pagine10
RivistaFuture Oncology
Volume11
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Anilides
  • Antineoplastic Agents
  • Carcinoma, Basal Cell
  • Combined Modality Therapy
  • Consensus Development Conferences as Topic
  • Disease Management
  • Humans
  • Neoplasm Staging
  • Pyridines
  • Risk Factors
  • Skin Neoplasms
  • basal cell carcinoma
  • locally advanced basal cell carcinoma
  • therapy
  • vismodegib

Fingerprint Entra nei temi di ricerca di 'Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus'. Insieme formano una fingerprint unica.

Cita questo